Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality

International Journal of Antimicrobial Agents

Volumn 55, Issue 5, 2020, Pages

  Zhang, Chi ^a   Wu, Zhao ^a   Li, Jia Wen ^a   Zhao, Hong ^a,b   Wang, Gui Qiang ^a,b,c  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c PEKING UNIVERSITY INTERNATIONAL HOSPITAL   (China)

Author keywords

COVID 19; Cytokine release syndrome; IL 6; IL 6R; Tocilizumab

Indexed keywords

INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; TOCILIZUMAB; IL6R PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ARTICLE; B LYMPHOCYTE; CORONAVIRUS DISEASE 2019; CYTOKINE RELEASE SYNDROME; DISEASE SEVERITY; HEMATOPOIETIC STEM CELL; HUMAN; LIVER CELL; MORTALITY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION; T LYMPHOCYTE; BETACORONAVIRUS; COMPLICATION; CORONAVIRUS INFECTION; PANDEMIC; SEVERITY OF ILLNESS INDEX; VIRUS PNEUMONIA;

ANTIBODIES, MONOCLONAL, HUMANIZED; BETACORONAVIRUS; CORONAVIRUS INFECTIONS; CYTOKINE RELEASE SYNDROME; HUMANS; PANDEMICS; PNEUMONIA, VIRAL; RECEPTORS, INTERLEUKIN-6; SEVERITY OF ILLNESS INDEX;

EID: 85082876722     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2020.105954     Document Type: Article

References (57)

1. Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395 (2020), 497–506.
2. Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med, 2020 Feb 18, 10.1016/S2213-2600(20)30076-X [Epub ahead of print]Erratum in: Lancet Respir Med 2020 Feb 25 [Epub ahead of print]. doi: 10.1016/S2213-2600(20)30085-0.
3. Miossec, P., Kolls, J.K., Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov 11 (2012), 763–776.
4. Shimabukuro-Vornhagen, A., Gödel, P., Subklewe, M., Stemmler, H.J., Schlößer, H.A., Schlaak, M., et al. Cytokine release syndrome. J Immunother Cancer, 6, 2018, 56.
5. Norelli, M., Camisa, B., Barbiera, G., Falcone, L., Purevdorj, A., Genua, M., et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med 24 (2018), 739–748.
6. Teijaro, J.R., Cytokine storms in infectious diseases. Semin Immunopathol 39 (2017), 501–503.
7. Chousterman, B.G., Swirski, F.K., Weber, G.F., Cytokine storm and sepsis disease pathogenesis. Semin Immunopathol 39 (2017), 517–528.
8. Leiva-Juarez, M.M., Kolls, J.K., Evans, S.E., Lung epithelial cells: therapeutically inducible effectors of antimicrobial defense. Mucosal Immunol 11 (2018), 21–34.
9. Knudsen, L., Ochs, M., The micromechanics of lung alveoli: structure and function of surfactant and tissue components. Histochem Cell Biol 150 (2018), 661–676.
10. Brune, K., Frank, J., Schwingshackl, A., Finigan, J., Sidhaye, V.K., Pulmonary epithelial barrier function: some new players and mechanisms. Am J Physiol Lung Cell Mol Physiol 308 (2015), L731–L745.
11. Liu, Q., Wang, R.S., Qu, G.Q., Wang, Y.Y., Liu, P., Zhu, Y.Z., et al. Gross examination report of a COVID-19 death autopsy. Fa Yi Xue Za Zhi [Journal of Forensic Medicine] 36 (2020), 19–21.
12. Scheller, J., Rose-John S. Interleukin-6 and its receptor: from bench to bedside. Med Microbiol Immunol 195 (2006), 173–183.
13. Weissenbach, J., Chernajovsky, Y., Zeevi, M., Shulman, L., Soreq, H., Nir, U., et al. Two interferon mRNAs in human fibroblasts: in vitro translation and Escherichia coli cloning studies. Proc Natl Acad Sci U S A 77 (1980), 7152–7156.
14. Hunter, C.A., Jones, S.A., IL-6 as a keystone cytokine in health and disease. Nat Immunol 16 (2015), 448–457 Erratum in: Nat Immunol 2017;18:1271.
15. Scheller, J., Garbers, C., Rose-John, S., Interleukin-6: from basic biology to selective blockade of pro-inflammatory activities. Semin Immunol 26 (2014), 2–12.
16. Jones, S.A., Jenkins, B.J., Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat Rev Immunol 18 (2018), 773–789.
17. Yamasaki, K., Taga, T., Hirata, Y., Yawata, H., Kawanishi, Y., Seed, B., et al. Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor. Science 241 (1988), 825–828.
18. Baran, P., Hansen, S., Waetzig, G.H., Akbarzadeh, M., Lamertz, L., Huber, H.J., et al. The balance of interleukin (IL)-6, IL-6•soluble IL-6 receptor (sIL-6R), and IL-6•sIL-6R•sgp130 complexes allows simultaneous classic and trans-signaling. J Biol Chem 293 (2018), 6762–6775.
19. Briso, E.M., Dienz, O., Rincon, M., Cutting edge: soluble IL-6R is produced by IL-6R ectodomain shedding in activated CD4 T cells. J Immunol 180 (2008), 7102–7106.
20. Campbell, I.L., Erta, M., Lim, S.L., Frausto, R., May, U., Rose-John, S., et al. Trans-signaling is a dominant mechanism for the pathogenic actions of interleukin-6 in the brain. J Neurosci 34 (2014), 2503–2513.
21. Jones, S.A., Directing transition from innate to acquired immunity: defining a role for IL-6. J Immunol 175 (2005), 3463–3468.
22. Johnson, D.E., O'Keefe, R.A., Grandis, J.R., Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol 15 (2018), 234–248.
23. Villarino, A.V., Kanno, Y., O'Shea, J.J., Mechanisms and consequences of Jak-STAT signaling in the immune system. Nat Immunol 18 (2017), 374–384.
24. Zegeye, M.M., Lindkvist, M., Falker, K., Kumawat, A.K., Paramel, G., Grenegård, M., et al. Activation of the JAK/STAT3 and PI3K/AKT pathways are crucial for IL-6 trans-signaling-mediated pro-inflammatory response in human vascular endothelial cells. Cell Commun Signal, 16, 2018, 55.
25. Su, H., Lei, C.T., Zhang, C., Interleukin-6 signaling pathway and its role in kidney disease: an update. Front Immunol, 8, 2017, 405.
26. Heinrich, P.C., Behrmann, I., Haan, S., Hermanns, H.M., Müller-Newen, G., Schaper, F., Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374 (2003), 1–20.
27. Taniguchi, K., Wu, L.W., Grivennikov, S.I., de Jong, P.R., Lian, I., Yu, F.X., et al. A gp130-Src-YAP module links inflammation to epithelial regeneration. Nature 519 (2015), 57–62.
28. Yamada, O., Ozaki, K., Akiyama, M., Kawauchi, K., JAK-STAT and JAK-PI3K-mTORC1 pathways regulate telomerase transcriptionally and posttranslationally in ATL cells. Mol Cancer Ther 11 (2012), 1112–1121.
29. Thiem, S., Pierce, T.P., Palmieri, M., Putoczki, T.L., Buchert, M., Preaudet, A., et al. mTORC1 inhibition restricts inflammation-associated gastrointestinal tumorigenesis in mice. J Clin Invest 123 (2013), 767–781.
30. Yasukawa, K., Hirano, T., Watanabe, Y., Muratani, K., Matsuda, T., Nakai, S., et al. Structure and expression of human B cell stimulatory factor-2 (BSF-2/IL-6) gene. EMBO J 6 (1987), 2939–2945.
31. Jones, B.E., Maerz, M.D., Buckner, J.H., IL-6: a cytokine at the crossroads of autoimmunity. Curr Opin Immunol 55 (2018), 9–14.
32. Kimura, A., Kishimoto, T., IL-6: regulator of Treg/Th17 balance. Eu J Immunol 40 (2010), 1830–1835.
33. Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T.B., Oukka, M., et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441 (2006), 235–238.
34. Schmidt-Arras, D., Rose-John, S., IL-6 pathway in the liver: from physiopathology to therapy. J Hepatol 64 (2016), 1403–1415.
35. Fraunberger, P., Wang, Y., Holler, E., Parhofer, K.G., Nagel, D., Walli, A.K., et al. Prognostic value of interleukin 6, procalcitonin, and C-reactive protein levels in intensive care unit patients during first increase of fever. Shock 26 (2006), 10–12.
36. + cells. Stem Cells 24 (2006), 1302–1314.
37. Kraakman, M.J., Kammoun, H.L., Allen, T.L., Deswaerte, V., Henstridge, D.C., Estevez, E., et al. Blocking IL-6 trans-signaling prevents high-fat diet-induced adipose tissue macrophage recruitment but does not improve insulin resistance. Cell Metab 21 (2015), 403–416.
38. Qu, D., Liu, J., Lau, C.W., Huang, Y., IL-6 in diabetes and cardiovascular complications. Br J Pharmacol 171 (2014), 3595–3603.
39. Navarro, G., Taroumian, S., Barroso, N., Duan, L., Furst, D., Tocilizumab in rheumatoid arthritis: a meta-analysis of efficacy and selected clinical conundrums. Semin Arthritis Rheum 43 (2014), 458–469.
40. Yokota, S., Miyamae, T., Imagawa, T., Iwata, N., Katakura, S., Mori, M., et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 52 (2005), 818–825.
41. Nishimoto, N., Kanakura, Y., Aozasa, K., Johkoh, T., Nakamura, M., Nakano, S., et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 106 (2005), 2627–2632.
42. Ito, H., Takazoe, M., Fukuda, Y., Hibi, T., Kusugami, K., Andoh, A., et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 126 (2004), 989–996 discussion 947.
43. Grupp, S.A., Kalos, M., Barrett, D., Aplenc, R., Porter, D.L., Rheingold, S.R., et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368 (2013), 1509–1518.
44. Winkler, U., Jensen, M., Manzke, O., Schulz, H., Diehl, V., Engert, A., Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 94 (1999), 2217–2224.
45. Genentech, Inc. Prescribing information. ACTEMRA® (tocilizumab) injection, for intravenous or subcutaneous use. 2019, Genentech, Inc., South San Francisco, CA https://www.gene.com/download/pdf/actemra_prescribing.pdf [accessed 11 March 2020].
46. Xu X.L., Han M.F., Li T.T., Sun W., Wang D.S., Fu B.Q., et al. Effective treatment of severe COVID-19 patients with tocilizumab. http://chinaxiv.org/abs/202003.00026[accessed 11 March 2020].
47. Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China [in Chinese]. Zhonghua Liu Xing Bing Xue Za Zhi 41 (2020), 145–151.
48. Giles, J.T., Sattar, N., Gabriel, S., Ridker, P.M., Gay, S., Warne, C., et al. Cardiovascular safety of tocilizumab versus etanercept in rheumatoid arthritis: a randomized controlled trial. Arthritis Rheumatol 72 (2020), 31–40.
49. Kim, S.C., Solomon, D.H., Rogers, J.R., Gale, S., Klearman, M., Sarsour, K., et al. Cardiovascular safety of tocilizumab versus tumor necrosis factor inhibitors in patients with rheumatoid arthritis: a multi-database cohort study. Arthritis Rheumatol 69 (2017), 1154–1164.
50. Xie, F., Yun, H., Levitan, E.B., Muntner, P., Curtis, J.R., Tocilizumab and the risk of cardiovascular disease: direct comparison among biologic disease-modifying antirheumatic drugs for rheumatoid arthritis patients. Arthritis Care Res 71 (2019), 1004–1018.
51. Le, R.Q., Li, L., Yuan, W., Shord, S.S., Nie, L., Habtemariam, B.A., et al. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. Oncologist 23 (2018), 943–947.
52. Teachey, D.T., Rheingold, S.R., Maude, S.L., Zugmaier, G., Barrett, D.M., Seif, A.E., et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood 121 (2013), 5154–5157.
53. Castilletti, C., Bordi, L., Lalle, E., Rozera, G., Poccia, F., Agrati, C., et al. Coordinate induction of IFN-α and -γ by SARS-CoV also in the absence of virus replication. Virology 341 (2005), 163–169.
54. Shi, S.Q., Peng, J.P., Li, Y.C., Qin, C., Liang, G.D., Xu, L., et al. The expression of membrane protein augments the specific responses induced by SARS-CoV nucleocapsid DNA immunization. Mol Immunol 43 (2006), 1791–1798.
55. Tseng, C.T., Perrone, L.A., Zhu, H., Makino, S., Peters, C.J., Severe acute respiratory syndrome and the innate immune responses: modulation of effector cell function without productive infection. J Immunol 174 (2005), 7977–7985.
56. Zheng, Y., Wang, Q.Y., Bioinformatics analysis on molecular mechanism of ribavirin and interferon-α in treating MERS-CoV [in Chinese]. Zhonghua Liu Xing Bing Xue Za Zhi 37 (2016), 291–293.
57. The State Council of the People's Republic of China. Diagnosis and treatment protocol for novel coronavirus pneumonia (seventh edition). http://www.gov.cn/zhengce/zhengceku/2020-03/04/5486705/files/ae61004f930d47598711a0d4cbf874a9.pdf[accessed 12 March 2020].